A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
Financial Summary
| Share Statistics | BIOGY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,192.3 | $288.9 | 47% |
|
| Shares Out (Mil) | 10.4 | 54.0 | 21% |
|
| Institutional Ownership | 44.7% | 93.1% | 19% |
|
| Float (Mil) | 83.9 | 41.4 | 58% |
|
| Beta | 0.32 | 0.94 | 19% |
|
| Avg Daily Volume (000s) | 1 | 480 | 4% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | BIOGY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.9% | 14.1% | 68% |
|
| Net Income (5yr) | 10.5% | (10.1%) | 56% |
|
| EPS (5yr) | 7.8% | 15.9% | 43 |
|
| Dividends (5yr) | 16.5% | 0.0% | 59% |
|
| Cash Flow (5yr) | (18.1%) | (15.6%) | 38% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BIOGY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $163 | $37 | 30% |
|
| Net Income (TTM) (Mil) | $36 | ($43) | 52% |
|
| EPS (TTM) | $0.354 | ($1.500) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $33 | ($31) | 44% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $2 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,257 | $190 | 43% |
|
| Valuation | BIOGY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BIOGY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.0% | 66.9% | 83% |
|
| Net Margin | 22.0% | (74.2%) | 81% |
|
| ROA | 24.8% | (47.7%) | 98% |
|
| ROE | 30.5% | (55.0%) | 88% |
|
| Liabilities to Assets | 17.6% | 29.6% | 11% |
|
| F-Score | na | 3 | na |
|
BioGaia AB (publ) did not pass any screens on 9/2/2026.
